PropThink: BG-12 Gets Extended FDA Review, ELN Likely Up Today; Look To Sell Into Strength

[ACN Newswire] – By David MoskowitzWe have written about the pressure on shares of Elan Corp. (NYSE:ELN), which has been taking place in advance of the expected market entry of Biogen Idec’s (NASDAQ:BIIB) BG-12 treatment … more

View todays social media effects on BIIB

View the latest stocks trending across Twitter. Click to view dashboard